You can buy or sell Biogen and other stocks, options, ETFs, and crypto commission-free!
Biogen Inc. Common Stock, also called Biogen, is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Read More It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Big Biotech Needs Big M&A to Boost Their Beaten-Down Stocks
Text size The biotech giants are hungry. That’s the view of JPMorgan analyst Cory Kasimov, who in a new report out Wednesday laid out the case that investors should be looking out for major acquisitions by the big biotech firms like Amgen (ticker: AMGN), Gilead (GILD), and Biogen (BIIB). “We think it’s only a matter of time before large cap biotech pulls the trigger on meaningful transactions,” Kasimov wrote. For investors, it couldn’t come a moment too soon. The stocks of Amgen, Gilead, and Biogen are ...
Stocks making the biggest moves premarket: Alibaba, Zillow Group, Biogen, McDonald's, Beyond Meat & more
Traders work under monitors displaying 3M Co. signage on the floor of the New York Stock Exchange (NYSE) in New York. Check out the companies making headlines before the bell: Alibaba — The Chinese e-commerce giant beat estimates by a wide margin on both the top and bottom lines, driven both by increased user engagement and growth in its cloud business. Tilray — Tilray reported an adjusted quarterly loss of 27 cents per share, two cents larger than analysts were expecting. The Canadian marijuana producer...
Seeking AlphaMay 15
Britain's cost watchdog on board with Biogen's Spinraza
Britain's National Institute for Health and Care Excellence (NICE), the advisor to the National Health Service (NHS) on costs and care quality, has recommended routine access for Biogen's (NASDAQ:BIIB) SPINRAZA (nusinersen) for the treatment of infants, children and adults with 5q spinal muscular atrophy (SMA), including pre-symptomatic and symptomatic SMA Types 1, 2 and 3....
Expected Jul 23, Pre-Market